JPMorgan Chase & Co. 13D and 13G filings for Regeneron Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-22 12:01 pm Sale |
2025-03-31 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
JPMORGAN CHASE & CO JPM |
5,546,434 5.100% |
-1,673,002 (-23.17%) |
Filing |
| 2024-01-25 11:11 am Unchanged |
2023-12-29 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
JPMORGAN CHASE & CO JPM |
7,219,436 6.700% |
0 (Unchanged) |
Filing |
| 2024-01-25 11:10 am Purchase |
2023-12-29 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
JPMORGAN CHASE & CO JPM |
7,219,436 6.700% |
1,118,392 (+18.33%) |
Filing |
| 2023-01-11 12:09 pm Purchase |
2022-12-30 | 13G | Regeneron Pharmaceuticals, Inc. REGN |
JPMORGAN CHASE & CO JPM |
6,101,044 5.600% |
6,101,044 (New Position) |
Filing |